ArticleTranslational cancer research2026
Multi-omics integration identifies PON2 as a prognostic biomarker and mediator of tumor microenvironment remodeling in gallbladder cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gallbladder cancer (GBC) is an aggressive biliary tract malignancy with limited therapeutic options and poor prognosis. Tumor microenvironment (TME) remodeling contributes substantially to GBC progression; however, the molecular drivers linking malignant epithelial programs to microenvironmental alterations remain poorly defined. This study aimed to characterize the cellular ecosystem of GBC and identify clinically relevant molecular targets associated with tumor progression and TME remodeling. Methods: Single-cell RNA sequencing (RNA-seq) data from 10 GBC tissues and 4 matched adjacent normal tissues were analyzed to define the cellular landscape of GBC. Unsupervised clustering, cell-type annotation, and copy number variation analysis were used to characterize TME composition and identify malignant epithelial populations. Integrated analyses of single-cell transcriptomic, bulk RNA-seq, and tumor proteomic datasets were performed to screen candidate prognostic biomarkers. The clinical relevance of the candidate gene was evaluated by survival analysis and validated in clinical GBC specimens using immunohistochemistry and quantitative real-time polymerase chain reaction. Functional assays were conducted in GBC cell lines to assess its effects on tumor cell proliferation and migration. Cell-cell communication analysis was further used to explore potential interactions between malignant epithelial cells and non-malignant microenvironmental components. Results: Single-cell profiling revealed substantial cellular heterogeneity within the GBC microenvironment and identified malignant epithelial clones with distinct transcriptional programs. Multi-omics integration identified paraoxonase 2 (PON2) as a potential prognostic biomarker in GBC. Elevated PON2 expression was validated in clinical GBC specimens and was associated with worse overall survival. Conclusions: This multi-omics study identifies PON2 as a clinically relevant biomarker associated with GBC progression and TME remodeling. PON2 may serve as a prognostic indicator and potential therapeutic target, providing new insights into TME-directed translational strategies for GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.